Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 10655490
• 负责人: Giulio Francesco Draetta
• 金额: $ 1102.97万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-08-28 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10655490
• 关键词: Acceleration; Affect; Age; Area; Award; Basic Science; Behavioral Sciences; Biology; Budgets; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Cancer Survivorship; Caring; Catchment Area; Clinic; Clinical; Clinical Research; Clinical Research Protocols; Clinical Trials; Collaborations; Communities; Comprehensive Cancer Center; Dedications; Detection; Development; Diagnosis; Direct Costs; Drug Approval; E-learning; Early Diagnosis; Education; Educational Curriculum; Educational Models; Employee; Enrollment; Epigenetic Process; Exclusion; Faculty; Foundations; Future; Generations; Grant; Hospitals; Human; Image; Immunology; Institution; Interdisciplinary Study; Internet; Intervention; Investigation; Investments; Journals; Knowledge; Laboratories; Learning; Location; Malignant Neoplasms; Mentorship; Minority; Mission; Molecular Epidemiology; Moon; Morbidity - disease rate; NCI-Designated Cancer Center; Newly Diagnosed; Oncology; Outcome; Participant; Patient Care; Patients; Persons; Population; Population Research; Population Sciences; Prevention; Research; Research Personnel; Research Project Grants; Research Training; Resistance; Resource Sharing; Science; Services; Specimen; System; Technology; Texas; Therapeutic; Training; Training Programs; Training and Education; Translational Research; Translations; Universities; University of Texas M D Anderson Cancer Center; Vision; anticancer research; cancer genetics; cancer health disparity; cancer prevention; cancer risk; care seeking; clinical practice; community engagement; data integration; design; economic disparity; effective intervention; evidence base; graduate student; health disparity; human subject; improved; innovation; insight; member; mortality; multidisciplinary; operation; population based; prevent; programs; prospective; rare cancer; recruit; research clinical testing; standard of care; survivorship; targeted agent; tenure track; therapy design; treatment strategy; undergraduate education; undergraduate student

PROJECT SUMMARY/ABSTRACT MD Anderson Cancer Center is a comprehensive cancer center established within the University of Texas System in 1941. In 2017, the institution welcomed Peter Pisters, MD, as its fifth full-time president and PI of the CCSG. The mission of MD Anderson is to eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. MD Anderson is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. MD Anderson employed more than 19,530 people in FY17, including 1,743 faculty members, of whom 705 (40%) are CCSG program members. More than 137,000 people sought care at MD Anderson in FY17 of whom 20,839 were newly diagnosed cancer patients. Annual citations in Web of Science have increased 23% from 3,260 in 2013, to 4,009 in 2017, including 686 (17%) articles in journals with an impact factor >10, and 244 (6%) articles in journals with an impact factor >20. The total research budget increased 26% from $671M in 2013 to $844M in 2017. Direct cost NCI research grant support, excluding training grants and the CCSG, has increased 34%, from $67M in 2013 to $90M in 2018, with the largest number of NCI grants for any institution (>200), including 6 SPOREs, 4 P01s and 35 U awards. Research Programs have been reduced to 16 and support is requested for 14 shared resources. Since the last CCSG renewal, research has been strengthened with recruitment of 97 tenured and tenure track faculty, of whom 18 are supported by recruitment awards from CPRIT totaling $63M. Team science has been enhanced through institutional support of the MD Anderson's Moon Shots ($383M), focused on reducing mortality from 13 major cancers through multi-disciplinary efforts that build on research emerging from the CCSG programs. In FY17, 10,283 participants were enrolled in 1,108 interventional clinical research protocols, of which 936 were treatment (therapeutic) studies that accrued 6,271 subjects. Over the past decade MD Anderson investigators have contributed to the clinical evaluation of 72 of 130 FDA oncology drug approvals, either as a new entity or for a new indication, with 41 of these approvals since the last CCSG renewal. In addition to the main hospital, Houston Area Locations provide prospective, multidisciplinary care and supportive services, with an increasing emphasis on access to clinical trials including national studies. Cancer prevention and survivorship is a priority for MD Anderson with an emphasis on molecular epidemiology, behavioral science, clinical cancer prevention and early detection research to reduce the burden of cancer within Texas and worldwide.

项目概要/摘要 MD安德森癌症中心是德克萨斯大学内建立的综合性癌症中心 该系统于 1941 年建立。2017 年，该机构迎来了医学博士彼得·皮斯特 (Peter Pisters) 担任其第五任全职院长兼 PI CCSG。 MD 安德森癌症中心的使命是通过以下方式消除德克萨斯州、全国乃至全世界的癌症 整合患者护理、研究和预防的杰出计划，并通过教育 本科生和研究生、实习生、专业人士、员工和公众。 MD安德森是 完全致力于癌症研究，涉及基础、临床和人群的连续性 调查，重点是多学科转化研究。 MD 安德森雇用了超过 2017 财年共有 19,530 人，其中包括 1,743 名教职员工，其中 705 名（40%）是 CCSG 计划成员。 2017 财年，超过 137,000 人在 MD 安德森寻求治疗，其中 20,839 人新诊断出癌症 患者。 Web of Science 的年度引用量从 2013 年的 3,260 次增加到 2017 年的 4,009 次，增长了 23%，其中包括 686 (17%) 篇文章发表在影响因子 >10 的期刊上，244 (6%) 篇文章发表在影响因子大于 10 的期刊上 >20。研究预算总额从 2013 年的 6.71 亿美元增加到 2017 年的 8.44 亿美元，增长了 26%。 直接成本 NCI 研究 赠款支持（不包括培训赠款和 CCSG）增加了 34%，从 2013 年的 6700 万美元增加到 2018 年的 9000 万美元， 拥有所有机构中最多的 NCI 拨款（>200），包括 6 个 SPORE、4 个 P01 和 35 个 U 奖项。 研究计划已减少至 16 个，并请求支持 14 个共享资源。自从上次 CCSG 更新并加强了研究，招聘了 97 名终身教授和终身教授， 其中 18 人获得了 CPRIT 总计 6300 万美元的招聘奖励的支持。团队科学得到加强 通过MD安德森登月计划（3.83亿美元）的机构支持，重点关注将死亡率从13 通过以 CCSG 项目的研究为基础的多学科努力来防治主要癌症。在 2017 财年，10,283 名参与者参加了 1,108 项介入临床研究方案，其中 936 名是 治疗（治疗）研究涉及 6,271 名受试者。过去十年 MD 安德森研究人员 为 FDA 130 种肿瘤药物批准中的 72 种（无论是作为新实体还是作为新实体）的临床评估做出了贡献 自上次 CCSG 更新以来，已有 41 项获得批准。除了主要医院外， 休斯顿地区地点提供前瞻性、多学科护理和支持服务，并且越来越多 强调获得临床试验，包括国家研究。癌症预防和生存是首要任务 MD 安德森癌症中心，重点是分子流行病学、行为科学、临床癌症预防 以及早期检测研究，以减轻德克萨斯州和全世界的癌症负担。